Sichuan Haisco Pharma will invest $6 million in eXithera, a US biopharma developing a novel anti-coagulant, and will own China rights to the product. Haisco will be responsible for development, trials, registration and production in China, and it will pay eXithera royalties on any future sales. After the financing, Haisco will own 12.5% of eXithera, a portfolio company of Israel’s Clal Biotechnology Industries. Haisco has previously invested in several Israeli medical device companies, including Endospan, MST and Sensible.
Source: China Biotoday
